A case involving chronic venous occlusion in a patient with a recently constructed AV loop graft sheds light on the ...

What DefenCath does is that it prevents the risk of infection for patients using central venous catheters (CVCs ... The market cap is at $466.7 million as at 27 March 2025, for a share price ...

We've identified the following companies as similar to Central Glass Co., Ltd. because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to ...